| Code | CSB-RA004936MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to BSI-038, targeting CD40, a critical costimulatory receptor belonging to the tumor necrosis factor receptor superfamily. CD40 is predominantly expressed on antigen-presenting cells, including B lymphocytes, dendritic cells, and macrophages, where it plays a pivotal role in regulating adaptive immune responses and B cell activation. Upon binding with its ligand CD40L, this receptor initiates signaling cascades that promote immune cell proliferation, antibody class switching, and cytokine production. Dysregulation of CD40 signaling is implicated in various autoimmune disorders, inflammatory conditions, and hematological malignancies, making it a significant target for immunological research.
BSI-038 represents an agonistic anti-CD40 antibody that has been investigated for its potential to enhance antitumor immunity by activating dendritic cells and promoting T cell-mediated responses. This biosimilar provides researchers with a reliable tool for investigating CD40-mediated immune mechanisms, exploring therapeutic strategies in oncology and autoimmune disease models, and studying the fundamental biology of immune cell activation and regulation.
There are currently no reviews for this product.